Phaseline

Companies › Crescent Biopharma

Crescent Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CR-002–Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)Oct 2028
CR-001–Phase 1Locally Advanced / Metastatic Solid TumorsFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07909031CR-002Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)OncologyOct 2028
NCT07335497CR-001Phase 1Locally Advanced / Metastatic Solid TumorsOncologyFeb 2029

From the company's SEC filings

Cash of $172m on 2026-06-30; operating cash outflow about $58m a year; runway about 36 months at that burn, to Jun 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.